PRISM BioLab

Basic Information

Stock Code
206A
Industry
Pharmaceuticals
Category Detail
Biotechnology & Pharmaceuticals
Prefecture
Kanagawa Prefecture
Establishment Year
April 2012
Listing Year
July 2024
Official Website
https://prismbiolab.com/ja/
TSE Information
TSE Information
Yahoo! Finance
Yahoo! Finance
Other Companies
Kojin B, Wolves Hand, GNI Group, Heartseed, Hmcomm, Nexela Pharma, PeptiDream, SanBio, Helios, RenaScience, QualiPs, Takara Bio, Japan Tissue Engineering

Overview

PRISM BioLab is a bio-drug discovery company founded in 2012 and based in Kanagawa Prefecture, a growing emerging company in the pharmaceutical industry with strengths in efficient new drug development using AI technology.

Current Situation

PRISM BioLab is an emerging bio-venture in the pharmaceutical industry scheduled to list in July 2024. Its main business is the development of a drug discovery platform utilizing AI, differentiating itself from competitors through innovative bio-drug discovery technology. Headquartered in Kanagawa Prefecture, it is strengthening collaborations with domestic and international pharmaceutical companies. Through funding and third-party share allotments, it is accelerating R&D investments to achieve early commercialization of next-generation pharmaceuticals. It competes with rivals such as SanBio and PeptiDream in the industry while advancing improvements in new drug development efficiency via AI. Toward growth post-2025, it prioritizes sustainable technology development and social responsibility, setting global expansion as a strategic goal.

Trivia

Interesting Facts

  • Rapidly growing venture in AI drug discovery field
  • Featured multiple times in Nikkei reports as a company to watch
  • Conducted large-scale third-party allotment just before listing
  • Holds numerous technology patents in bio-drug discovery
  • Closely collaborating with universities in Kanagawa Prefecture
  • High attention as an emerging player in the industry
  • Industry pioneer in pharmaceutical development efficiency using AI
  • Actively conducting joint research with overseas institutions
  • Employs many young researchers to introduce innovative ideas
  • High market expectations for future blockbuster drug development
  • Fusing new technologies through alliances with diverse related companies
  • Applying technology to medical data analysis for broad deployment
  • Focusing on recruiting data scientists
  • Supporting global expansion with various international patents
  • Aiming to be the leading company in AI-based drug discovery support

Hidden Connections

  • Strengthened research support through capital participation from major domestic pharmaceutical companies
  • Contributing to network formation among research bases in Kanagawa Prefecture
  • Collaborating with IT companies on AI development for cross-industry alliances
  • Presented multiple research papers at international academic conferences
  • Applying technology to clinical testing equipment field for diversified expansion
  • Operating field research programs in collaboration with local medical institutions
  • Strengthening exclusivity through joint ownership of related pharmaceutical patents
  • Preparing for international expansion with some drug discovery AI technologies under overseas patent application

Future Outlook

Growth Drivers

  • Significant shortening of new drug development periods through AI utilization
  • Expansion of bio-drug discovery markets domestically and internationally
  • Strengthening alliances with global pharmaceutical companies
  • Revenue diversification through diverse drug discovery solutions
  • Establishment of sustainable R&D framework
  • Tailwinds from government bio-pharmaceutical support policies
  • Maintaining and enhancing competitiveness through cutting-edge technology adoption
  • Rising demand for efficient clinical data analysis

Strategic Goals

  • Achieve leadership in AI drug discovery platforms in global markets
  • Realize stable growth with annual sales exceeding ¥10 billion
  • Advance multiple new drug candidates to clinical trials
  • Improve social evaluation through sustainability activities
  • Expand joint research with technology partners
  • Promote technology application across diverse pharmaceutical fields
  • Strengthen talent development in collaboration with regions
  • Enhance and protect patent portfolio
  • Open new markets through fusion of AI and drug discovery technology
  • Build a culture of sustainable innovation

Business Segments

Drug Discovery Support for Pharmaceutical Companies

Overview
Supports pharmaceutical companies' new drug development with AI and bio technology.
Competitiveness
Integration of advanced AI analysis technology and R&D expertise
Customers
  • Major pharmaceutical companies
  • Bio ventures
  • Research and development institutions
  • University labs
  • Joint research organizations
Products
  • AI drug discovery platform
  • Gene analysis service
  • Molecular design software
  • Bio reagents
  • Data analysis cloud

Product Suite for Clinical Testing Institutions

Overview
Provides high-precision testing products and services for clinical use.
Competitiveness
Testing solutions pursuing accuracy and efficiency
Customers
  • Hospitals
  • Testing centers
  • Diagnostic labs
  • Medical device sales companies
Products
  • Biomarker detection kits
  • Automated testing devices
  • Gene abnormality analysis devices

Bio Reagent Supply for Research Institutions

Overview
Stable supply of essential reagents and consumables for bio research.
Competitiveness
High-quality product lineup considering cost efficiency
Customers
  • Universities
  • Public research institutions
  • Private research institutes
  • Pharmaceutical company labs
Products
  • DNA/RNA extraction reagents
  • PCR enzyme sets
  • Cell culture reagents

Bio Diagnostic Device Sales

Overview
Sales of high-sensitivity devices enabling rapid diagnosis.
Competitiveness
User-friendly device design equipped with the latest technology
Customers
  • Medical institutions
  • Testing institutions
  • Wholesalers
Products
  • PCR devices
  • Biosensors
  • Multiplex testing platforms

Drug Discovery Software Licensing

Overview
Provides a variety of software supporting drug discovery processes.
Competitiveness
Balance of usability and analysis accuracy
Customers
  • Pharmaceutical company R&D departments
  • Bio IT companies
Products
  • Molecular design tools
  • Pharmacokinetics analysis software

AI Technology Consulting

Overview
Provides one-stop proposals and support for AI utilization.
Competitiveness
Dual strengths of specialized AI technology and pharmaceutical knowledge
Customers
  • Pharmaceutical companies
  • Medical device manufacturers
Products
  • AI implementation support services
  • Drug discovery data analysis support

Clinical Trial Support Services

Overview
Support contributing to efficiency and accuracy improvement in clinical trials.
Competitiveness
Extensive experience in clinical data analysis
Customers
  • Pharmaceutical companies
  • CROs (contract research organizations)
Products
  • Biomarker analysis
  • Data management services

Competitive Advantage

Strengths

  • Possession of advanced AI drug discovery technology
  • High R&D capabilities specialized in bio-drug discovery
  • Network of partnerships with diverse related companies
  • Enhanced funding through listing
  • Advantages of research environment centered in Kanagawa Prefecture
  • Portfolio of patented proprietary technologies
  • Strength in early-phase pharmaceutical discovery
  • Flexible development system backed by highly skilled engineers
  • Increasing attention from the market
  • Unique platform fusing AI and bio

Competitive Advantages

  • Shortened new drug development timelines through AI adoption
  • Technology foundation integrating gene analysis and drug discovery support
  • High-precision predictions leveraging rich datasets
  • Product lineup spanning multiple areas
  • Pioneering provision of drug discovery AI platforms ahead of competitors
  • Improved R&D speed through strong business alliances
  • Expanded research investments via strengthened funding capabilities
  • Services adaptable to diverse needs of pharmaceutical companies
  • Efficient clinical data analysis incorporating cutting-edge technology
  • Continuous update system for AI technology

Threats

  • Development of similar AI drug discovery platforms by competitors
  • Fluctuations in stringent pharmaceutical regulations and approval processes
  • Ongoing burden of high R&D costs
  • Risk of obsolescence due to rapid technological evolution
  • Long periods until market launch and fund recovery
  • Intensifying competition in global markets
  • Challenges in talent retention and acquisition
  • Risk of intellectual property infringement
  • Explainability issues from black-box technology
  • Impacts from economic conditions and exchange rate fluctuations

Innovations

2024: Commercial Launch of AI Drug Discovery Platform

Overview
Officially released proprietary AI-based drug discovery support service.
Impact
Significantly improved new drug development efficiency, contributing to increased orders.

2023: Performance Upgrade of Gene Analysis Software

Overview
Released new version with improved analysis speed and accuracy.
Impact
Achieved higher customer satisfaction and increased contracts.

2022: Medical Device Approval for Biomarker Detection Kit

Overview
Obtained approval as a high-sensitivity testing kit for clinical use.
Impact
Sales increased with expanded adoption in medical institutions.

2021: Launch of Cloud-Based Analysis Service

Overview
Introduced cloud service capable of handling large data volumes.
Impact
Realized cost reduction in analysis and service expansion.

2020: Development of AI Analysis Tool for Clinical Trials

Overview
Developed and launched automated analysis tool for clinical data.
Impact
Contributed to clinical trial efficiency and customer base expansion.

Sustainability

  • Promoting energy-saving measures in research facilities to reduce environmental impact
  • Proper waste management and recycling promotion
  • Exploring adoption of sustainable bio materials
  • Strengthening employee health and safety management
  • Supporting environmental protection activities through collaboration with local communities
  • Exploring introduction of green chemistry in pharmaceutical processes
  • Setting ESG metrics for sustainable management
  • CO2 emission reductions through energy efficiency improvements
  • Promoting efficient resource utilization via AI technology
  • Sustainable development through open innovation